PT - JOURNAL ARTICLE AU - Croci, Susanna AU - Venneri, Mary Anna AU - Mantovani, Stefania AU - Fallerini, Chiara AU - Benetti, Elisa AU - Picchiotti, Nicola AU - Campolo, Federica AU - Imperatore, Francesco AU - Palmieri, Maria AU - Daga, Sergio AU - Gabbi, Chiara AU - Montagnani, Francesca AU - Beligni, Giada AU - Farias, Ticiana D.J. AU - Carriero, Miriam Lucia AU - Sarno, Laura Di AU - Alaverdian, Diana AU - Aslaksen, Sigrid AU - Cubellis, Maria Vittoria AU - Spiga, Ottavia AU - Baldassarri, Margherita AU - Fava, Francesca AU - Norman, Paul J. AU - Frullanti, Elisa AU - Isidori, Andrea M. AU - Amoroso, Antonio AU - Mari, Francesca AU - Furini, Simone AU - Mondelli, Mario U AU - , AU - Chiariello, Mario AU - Renieri, Alessandra AU - Meloni, Ilaria TI - The polymorphism L412F in <em>TLR3</em> inhibits autophagy and is a marker of severe COVID-19 in males AID - 10.1101/2021.03.23.21254158 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.23.21254158 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21254158.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.23.21254158.full AB - The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired autophagy and reduced TNFα production was demonstrated in HEK293 cells transfected with TLR3-L412F plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (P=0.038). An increased frequency of autoimmune disorders as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04549831Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04549831 Funding StatementWe thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). PJN was supported by a grant from fastgrants.org. We also thank the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/) and MIUR project Dipartimenti di Eccellenza 2018-2020 to the Department of Medical Biotechnologies University of Siena, Italy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GEN-COVID study was approved by the University Hospital of Siena Ethical Review Board (Protocol n. 16929, dated March 16, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it). http://nigdb.cineca.it https://sites.google.com/dbm.unisi.it/gen-covid